462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1819238978520350720 |
|---|---|
| author | Magnus Jaderberg Victor Levitsky Luis Paz-Ares Lukasz Kuryk Nicolas Isambert Susana Cedres Charles Ricordel Santiago Ponce Aix Anne-Sophie Moller Sylvia Vetrhus |
| author_facet | Magnus Jaderberg Victor Levitsky Luis Paz-Ares Lukasz Kuryk Nicolas Isambert Susana Cedres Charles Ricordel Santiago Ponce Aix Anne-Sophie Moller Sylvia Vetrhus |
| author_sort | Magnus Jaderberg |
| collection | DOAJ |
| first_indexed | 2024-12-23T13:44:49Z |
| format | Article |
| id | doaj.art-7b6dc7621b064d579ed8757704182e8d |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-23T13:44:49Z |
| publishDate | 2021-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-7b6dc7621b064d579ed8757704182e8d2022-12-21T17:44:45ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-11-019Suppl 210.1136/jitc-2021-SITC2021.462462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival dataMagnus Jaderberg0Victor Levitsky1Luis Paz-Ares2Lukasz Kuryk3Nicolas Isambert4Susana Cedres5Charles Ricordel6Santiago Ponce Aix7Anne-Sophie Moller8Sylvia Vetrhus91Research and Development, Oslo, Norway1Research and Development, Oslo, NorwayH12O-CNIO Lung Cancer Clinical Research Unit, Health Research Institute Hospital 12 de Octubre (imas12) / Spanish National Cancer Research Center (CNIO), Madrid, Spain1Research and Development, Oslo, Norway2Medical Oncology, Sevilla, Spain2Medical Oncology, Sevilla, SpainDepartment of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France2Medical Oncology, Sevilla, Spain1Research and Development, Oslo, Norway1Research and Development, Oslo, Norway |
| spellingShingle | Magnus Jaderberg Victor Levitsky Luis Paz-Ares Lukasz Kuryk Nicolas Isambert Susana Cedres Charles Ricordel Santiago Ponce Aix Anne-Sophie Moller Sylvia Vetrhus 462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data Journal for ImmunoTherapy of Cancer |
| title | 462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data |
| title_full | 462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data |
| title_fullStr | 462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data |
| title_full_unstemmed | 462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data |
| title_short | 462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data |
| title_sort | 462 a randomised open label phase i ii study adding oncos 102 to pemetrexed cisplatin in patients with unresectable malignant pleural mesothelioma 24 month survival data |
| work_keys_str_mv | AT magnusjaderberg 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT victorlevitsky 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT luispazares 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT lukaszkuryk 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT nicolasisambert 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT susanacedres 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT charlesricordel 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT santiagoponceaix 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT annesophiemoller 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata AT sylviavetrhus 462arandomisedopenlabelphaseiiistudyaddingoncos102topemetrexedcisplatininpatientswithunresectablemalignantpleuralmesothelioma24monthsurvivaldata |